Genmab announces new results fom Phase 1b/2 EPCORE NHL-2 trial

Genmab (GMAB) announced new results from the Phase 1b/2 EPCORE NHL-2 trial Arm 10, evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and etoposide, R-ICE, in adult patients with relapsed/refractory diffuse large B-cell lymphoma, R/R DLBCL, who are eligible for autologous stem cell transplantation, ASCT. Results demonstrated an overall response rate, ORR, of 87 percent, a complete response rate of 65 percent and a partial response of 23 percent. The majority of patients proceeded to ASCT. At six months, an estimated 81 percent of responses were ongoing, 74 percent of patients were progression free, and 100 percent of patients were alive. These results were shared today during an oral presentation at the 30th European Hematology Association 2025 Congress. The safety profile of this combination therapy showed cytokine release syndrome being low grade and no discontinuations due to treatment-emergent adverse events. The most common TEAEs were neutropenia, anemia, and thrombocytopenia. CRS occurred in 52 percent; all were low grade and resolved. One patient had immune effector cell-associated neurotoxicity syndrome, which resolved. No clinical tumor lysis syndrome was observed. Infections occurred in 18 patients; five had serious infections. There were no Grade 5 TEAEs.